Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmine M Zain

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
American Journal of Hematology|May 24, 2019
Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and managementJasmine M Zain
American Journal of Hematology|June 10, 2021
Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and managementJasmine M Zain, Paul Hanona
International Journal of Hematology|June 11, 2010
Targeted treatment and new agents in peripheral T-cell lymphomaJasmine M Zain, Owen O'Connor
Drugs of Today (Barcelona, Spain : 1998)|April 16, 2010
Pralatrexate - from bench to bedsideJasmine M Zain, E Marchi
American Journal of Hematology|February 2, 2024
Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and managementShin Yeu Ong, Jasmine M Zain
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and TherapiesJonathon B Cohen, Jasmine M Zain, Brad S Kahl
Current Opinion in Oncology|July 12, 2018
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experienceAlecia S Folkes, Mingye Feng, Jasmine M Zain, et al.
Journal of Clinical Pharmacy and Therapeutics|January 13, 2022
Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapyJana K Dickter, Justine A Ross, Jasmine M Zain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignanciesEnrica Marchi, Luca Paoluzzi, Luigi Scotto, et al.
Leukemia & Lymphoma|August 10, 2011
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517Mark H Kirschbaum, Bryan H Goldman, Jasmine M Zain, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
American Journal of Hematology|May 24, 2019
Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and managementJasmine M Zain
American Journal of Hematology|June 10, 2021
Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and managementJasmine M Zain, Paul Hanona
International Journal of Hematology|June 11, 2010
Targeted treatment and new agents in peripheral T-cell lymphomaJasmine M Zain, Owen O'Connor
Drugs of Today (Barcelona, Spain : 1998)|April 16, 2010
Pralatrexate - from bench to bedsideJasmine M Zain, E Marchi
American Journal of Hematology|February 2, 2024
Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and managementShin Yeu Ong, Jasmine M Zain
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and TherapiesJonathon B Cohen, Jasmine M Zain, Brad S Kahl
Current Opinion in Oncology|July 12, 2018
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experienceAlecia S Folkes, Mingye Feng, Jasmine M Zain, et al.
Journal of Clinical Pharmacy and Therapeutics|January 13, 2022
Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapyJana K Dickter, Justine A Ross, Jasmine M Zain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignanciesEnrica Marchi, Luca Paoluzzi, Luigi Scotto, et al.
Leukemia & Lymphoma|August 10, 2011
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517Mark H Kirschbaum, Bryan H Goldman, Jasmine M Zain, et al.
Pageof 3